Pfreundschuh M, et al. - Authors here investigated higher rituximab doses for elderly male diffuse large B-cell lymphoma (DLBCL) patients. In these elderly, the higher rituximab dose seemed to abrogate the adverse prognosis of male sex without increasing toxicity. In the era of personalized medicine, they suggested investigating sex-specific pharmacokinetics and toxicities for all drugs where these parameters impact on outcome.